Cargando…
Cost-Effectiveness of Short Course of Ceftazidime/Avibactam for K. pneumoniae-KPC Bloodstream Infections in Italy
Background: Evidence has shown that short courses of antibiotic therapy are at least as effective as long courses with better clinical outcomes. CAZ/AVI has demonstrated its clinical efficacy in treating K. pneumoniae-KPC infections. Methods: We conducted an analysis based on the real-life data of o...
Autores principales: | De Benedetto, Ilaria, Shbaklo, Nour, Vicentini, Costanza, Zotti, Carla Maria, De Rosa, Francesco Giuseppe, Corcione, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224085/ https://www.ncbi.nlm.nih.gov/pubmed/37317076 http://dx.doi.org/10.3390/microorganisms11051102 |
Ejemplares similares
-
Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with?
por: Corcione, Silvia, et al.
Publicado: (2023) -
In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021) -
Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022) -
Neonatal Bloodstream Infection with Ceftazidime-Avibactam-Resistant bla(KPC-2)-Producing Klebsiella pneumoniae Carrying bla(VEB-25)
por: Zarras, Charalampos, et al.
Publicado: (2023) -
Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study
por: Campogiani, Laura, et al.
Publicado: (2023)